BITD401412 / Boston Immune Tech - LARVOL DELTA

BITT Announced CD40 Otsuka Research and Exclusivity Agreement and New NIH Funding for TNFR2 Clinical Trial (Businesswire) - "Boston Immune Technologies and Therapeutics, Inc...announced today a sponsored research and exclusivity agreement with the McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies. MSRD will finance key non-human primate studies for the pre-clinical development of BITT’s CD40 antagonist in exchange for an exclusive right to negotiate an acquisition, license or collaboration agreement related to the asset. BITT is also announcing that it has also been awarded a $4M National Institute of Health/National Cancer Institute to support the ongoing Phase I clinical trial of BITT’s lead TNFR2 antagonist. 'Our agreement with Otsuka will provide significant resources in furtherance of our goal of filing an IND related to our CD40 antagonist program in 2025'."

Financing • IND • Oncology

BITT Announces NIH Award for Advancement of Anti-CD40 Antibody (Businesswire) - "Boston Immune Technologies and Therapeutics, Inc...announced today the award of funding from the National Institutes of Health (NIH) to support the preclinical development of BITT’s CD40 antagonist antibody. The award for Advancing BITT-101: A Novel Dominant CD40 Antagonist for Use in the Treatment of Sjögren’s Syndrome will help support steps toward an IND filing in 2024....In preclinical studies, BITT antibodies exhibited the ability to deplete B cells and inhibit IgG levels – including a unique ability to selectively deplete activated (CD86+) and younger B cells making early IgM antibodies."

Financing • IND • Preclinical • Immunology • Sjogren's Syndrome